Literature DB >> 4858417

Comparison of amantadine, placebo, and levodopa in Parkinson's disease.

R B Bauer, J T McHenry.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4858417     DOI: 10.1212/wnl.24.8.715

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  7 in total

1.  Tremor in Parkinson disease: acute response to oral levodopa.

Authors:  G Tedeschi; E Sasso; R W Marshall; V Bonavita
Journal:  Ital J Neurol Sci       Date:  1990-06

Review 2.  Economic and health-related quality of life considerations of new therapies in Parkinson's disease.

Authors:  L M Rubenstein; A DeLeo; E A Chrischilles
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations.

Authors:  M Brenner; A Haass; P Jacobi; K Schimrigk
Journal:  J Neurol       Date:  1989-03       Impact factor: 4.849

4.  Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect.

Authors:  G M Pacifici; M Nardini; P Ferrari; R Latini; C Fieschi; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

Review 5.  Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective.

Authors:  D R Guay
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

Review 6.  Amantadine in Parkinson's disease.

Authors:  N Crosby; K H Deane; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2003

7.  SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration.

Authors:  Alice Lippi; Renato Domingues; Cristian Setz; Tiago F Outeiro; Anita Krisko
Journal:  Mov Disord       Date:  2020-04-24       Impact factor: 10.338

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.